                         SEQUENCE LISTING

<110>  Avipep Pty Ltd
 
<120>  IMMUNO-CONJUGATES AND METHODS FOR PRODUCING THEM 2

<130>  509431

<150>  US61/289497
<151>  2009-12-23

<160>  157   

<170>  PatentIn version 3.5

<210>  1
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody heavy chain

<400>  1

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser 
1               5                   10                  


<210>  2
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody heavy chain

<400>  2

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly 
1               5                   10                  


<210>  3
<211>  13
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody heavy chain

<400>  3

Trp Val Arg Gln Ala Pro Gly Gln Leu Glu Trp Met Gly 
1               5                   10              


<210>  4
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody heavy chain

<400>  4

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly 
1               5                   10                  


<210>  5
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody heavy chain

<400>  5

Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly 
1               5                   10                  


<210>  6
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody heavy chain

<400>  6

Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Gly 
1               5                   10                  


<210>  7
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody heavy chain

<400>  7

Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly 
1               5                   10                  


<210>  8
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody heavy chain

<400>  8

Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly 
1               5                   10                  


<210>  9
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody kappa light chain

<400>  9

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  10
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody kappa light chain

<400>  10

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  11
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody kappa light chain

<400>  11

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  12
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody kappa light chain

<400>  12

Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  13
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody kappa light chain

<400>  13

Trp Tyr Gln Gln Lys Pro Cys Gln Ala Pro Arg Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  14
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody kappa light chain

<400>  14

Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr 
1               5                   10                  15  


<210>  15
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody kappa light chain

<400>  15

Trp Tyr Gln Gln Lys Pro Ala Lys Ala Pro Lys Leu Phe Ile Tyr 
1               5                   10                  15  


<210>  16
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody kappa light chain

<400>  16

Trp Tyr Leu Gln Lys Pro Gly Gln Pro Pro Gln Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  17
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody lambda light chain

<400>  17

Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  18
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody lambda light chain

<400>  18

Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr 
1               5                   10                  15  


<210>  19
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody lambda light chain

<400>  19

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
1               5                   10                  15  


<210>  20
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody lambda light chain

<400>  20

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 
1               5                   10                  15  


<210>  21
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR2 of a human antibody lambda light chain

<400>  21

Trp His Gln Gln Gln Pro Glu Lys Gly Pro Arg Tyr Leu Met Tyr 
1               5                   10                  15  


<210>  22
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  22

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  23
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  23

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu His Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg 
            20                  25                  30          


<210>  24
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  24

Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg 
            20                  25                  30          


<210>  25
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  25

Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys 
1               5                   10                  15      


Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  26
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  26

Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr 
1               5                   10                  15      


Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  27
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  27

Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln 
1               5                   10                  15      


Met Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  28
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  28

Arg Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln 
1               5                   10                  15      


Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  29
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  29

Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu 
1               5                   10                  15      


Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  30
<211>  33
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  30

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys 
            20                  25                  30          


Asp 
    


<210>  31
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  31

Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu 
1               5                   10                  15      


Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  32
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  32

Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr Met Glu 
1               5                   10                  15      


Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  33
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  33

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu His Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Lys Lys 
            20                  25                  30          


<210>  34
<211>  33
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  34

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys 
            20                  25                  30          


Asp 
    


<210>  35
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  35

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  36
<211>  33
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  36

Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr 
1               5                   10                  15      


Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg 
            20                  25                  30          


Ile 
    


<210>  37
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  37

Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln 
1               5                   10                  15      


Ile Cys Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  38
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  38

Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn Gln Phe Ser Leu Gln 
1               5                   10                  15      


Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  39
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  39

His Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln 
1               5                   10                  15      


Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  40
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody heavy chain

<400>  40

Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu 
1               5                   10                  15      


Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  41
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody kappa light chain

<400>  41

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  42
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody kappa light chain

<400>  42

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  43
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody kappa light chain

<400>  43

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  44
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody kappa light chain

<400>  44

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys 
            20                  25                  30          


<210>  45
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody kappa light chain

<400>  45

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys 
            20                  25                  30          


<210>  46
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody kappa light chain

<400>  46

Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys 
            20                  25                  30          


<210>  47
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody kappa light chain

<400>  47

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys 
            20                  25                  30          


<210>  48
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody kappa light chain

<400>  48

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys 
            20                  25                  30          


<210>  49
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody lambda light chain

<400>  49

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Cys Leu Gln Ser Glu Asp Phe Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  50
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody lambda light chain

<400>  50

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  51
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody lambda light chain

<400>  51

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Pro Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys 
            20                  25                  30          


<210>  52
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody lambda light chain

<400>  52

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Asn Ser Leu Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  53
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody lambda light chain

<400>  53

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys 
            20                  25                  30          


<210>  54
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody lambda light chain

<400>  54

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Phe Thr Ile Ser Ser Leu Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  55
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody lambda light chain

<400>  55

Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Tyr Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Asn Asn Ile Glu Ser Glu Asp Ala Ala Tyr Tyr Phe Cys 
            20                  25                  30          


<210>  56
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  amino acid sequence of FR3 of a human antibody lambda light chain

<400>  56

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  57
<211>  5
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of a linker

<400>  57

Gly Gly Gly Gly Ser 
1               5   


<210>  58
<211>  711
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence encoding AVP04-07 anti TAG72 diabody

<400>  58
caggtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag cccgagcagc ctgccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagc agaaaccggg tcagagcccg aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc agcggtagcg gcaccgattt taccctgagc      600

attagcagcg tggaaaccga agatctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc g               711


<210>  59
<211>  245
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of AVP04-07 anti-TAG72 diabody

<400>  59

Gln Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro 
        115                 120                 125             


Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr Glu Asp 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  60
<211>  804
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence encoding AVP07-17 anti-Her2 diabody

<400>  60
caggtgcagc tggtgcagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc       60

tcctgtaagg gttctggata cagctttacc agctactgga tcgcctgggt gcgccagatg      120

cccgggaaag gcctggagta catggggctc atctatcctg gtgactctga caccaaatac      180

agcccgtcct tccaaggcca ggtcaccatc tcagtcgaca agtccgtcag cactgcctac      240

ttgcaatgga gcagtctgaa gccctcggac agcgccgtgt atttttgtgc gagacatgac      300

gtgggatatt gcagtagttc caactgcgca aagtggcctg aatacttcca gcattggggc      360

cagggcaccc tggtcaccgt ttcctcaggt ggaggcggtt cacagtctgt gttgacgcag      420

ccgccctcag tgtctgcggc cccaggacag aaggtcacca tctcctgctc tggaagcagc      480

tccaacattg ggaataatta tgtatcctgg taccagcagc tcccaggaac agtccccaaa      540

ctcctcatct atggtcacac caatcggccc gcaggggtcc ctgaccgatt ctctggctcc      600

aagtctggca cctcagcctc cctggccatc agtgggttcc ggtccgagga tgaggctgat      660

tattactgtg cagcatggga tgacagcctg agtggttggg tgttcggcgg agggaccaag      720

ctgaccgtcc taggtgcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg      780

gccgcacatc accatcatca ccat                                             804


<210>  61
<211>  268
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of AVP07-17 anti-Her2 diabody

<400>  61

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Tyr Met 
        35                  40                  45              


Gly Leu Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Pro Ser Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Asp Val Gly Tyr Cys Ser Ser Ser Asn Cys Ala Lys Trp 
            100                 105                 110         


Pro Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val 
    130                 135                 140                 


Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser 
145                 150                 155                 160 


Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly 
                165                 170                 175     


Thr Val Pro Lys Leu Leu Ile Tyr Gly His Thr Asn Arg Pro Ala Gly 
            180                 185                 190         


Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu 
        195                 200                 205             


Ala Ile Ser Gly Phe Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala 
    210                 215                 220                 


Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys 
225                 230                 235                 240 


Leu Thr Val Leu Gly Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu 
                245                 250                 255     


Asp Leu Asn Gly Ala Ala His His His His His His 
            260                 265             


<210>  62
<211>  729
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence encoding AVP02-60 anti-MucI diabody

<400>  62
gaagtgcagc tggttgaaag cggtggcgga gtggtgcagc caggtggaag cctgcgtctg       60

agctgcgcag caagcggttt tacctttagc agctatggca tgagctgggt gcgtcaggcg      120

ccggataaag gcctggaact ggtggcgacc attaacagca acggtggaag cacctattat      180

ccggatagcg tgaaaggccg ttttaccatt agccgtgata acagcaaaaa caccctgtat      240

ctgcagatga acagcctgcg taccgaagat accgcggtgt attattgcgc gcgtgatcgt      300

gatggctatg atgaaggctt tgattattgg ggccagggca ccctggtgac cgtgagcagc      360

ggtgggggcg gaagccagat tcagctgacc cagagcccga gcagcctgag cgcaagcgtg      420

ggtgatcgtg tgaccattac ctgcagcgcg agcagcagcg tgagctatat gcattggtat      480

cagcagaaac cgggcaaagc gccgaaacgt tggatttatg ataccagcaa actggcgagc      540

ggcgtgccga gccgttttag cggcagcggc agcggcaccg attatacctt taccattagc      600

agcctgcagc cggaagatat tgcgacctat tattgccagc agtggagcag caacccgccg      660

acctttggcc agggcaccaa actgcagatt aaacgtgcgg ccgcactcga gcaccaccac      720

caccaccac                                                              729


<210>  63
<211>  243
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of AVP02-60 anti-MucI diabody

<400>  63

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Ala Pro Asp Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Thr Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Asp Gly Tyr Asp Glu Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Ile Gln 
        115                 120                 125             


Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val 
    130                 135                 140                 


Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr 
145                 150                 155                 160 


Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser 
                165                 170                 175     


Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
            180                 185                 190         


Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala 
        195                 200                 205             


Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr Phe Gly Gln 
    210                 215                 220                 


Gly Thr Lys Leu Gln Ile Lys Arg Ala Ala Ala Leu Glu His His His 
225                 230                 235                 240 


His His His 
            


<210>  64
<211>  804
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence encoding a modified AVP07-17 anti-HER2 
       diabody replacing CDR3H Cysteine residues Cys104 (Kabat numbering
       H100) and Cys109 (H100E) with Alanines and comprising a 
       N-terminal serine designated AVP07-86

<400>  64
agcgtgcagc tggtgcagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc       60

tcctgtaagg gttctggata cagctttacc agctactgga tcgcctgggt gcgccagatg      120

cccgggaaag gcctggagta catggggctc atctatcctg gtgactctga caccaaatac      180

agcccgtcct tccaaggcca ggtcaccatc tcagtcgaca agtccgtcag cactgcctac      240

ttgcaatgga gcagtctgaa gccctcggac agcgccgtgt atttttgtgc gagacatgac      300

gtgggatatg cgagtagttc caacgcggca aagtggcctg aatacttcca gcattggggc      360

cagggcaccc tggtcaccgt ttcctcaggt ggaggcggtt cacagtctgt gttgacgcag      420

ccgccctcag tgtctgcggc cccaggacag aaggtcacca tctcctgctc tggaagcagc      480

tccaacattg ggaataatta tgtatcctgg taccagcagc tcccaggaac agtccccaaa      540

ctcctcatct atggtcacac caatcggccc gcaggggtcc ctgaccgatt ctctggctcc      600

aagtctggca cctcagcctc cctggccatc agtgggttcc ggtccgagga tgaggctgat      660

tattactgtg cagcatggga tgacagcctg agtggttggg tgttcggcgg agggaccaag      720

ctgaccgtcc taggtgcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg      780

gccgcacatc accatcatca ccat                                             804


<210>  65
<211>  268
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of modified AVP07-17 anti-HER2 diabody 
       replacing CDR3H Cysteine residues Cys104 (Kabat numbering H100) 
       and Cys109 (H100E) with Alanines and comprising a N-terminal 
       serine designated AVP07-86

<400>  65

Ser Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Tyr Met 
        35                  40                  45              


Gly Leu Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Pro Ser Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Asp Val Gly Tyr Ala Ser Ser Ser Asn Ala Ala Lys Trp 
            100                 105                 110         


Pro Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val 
    130                 135                 140                 


Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser 
145                 150                 155                 160 


Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly 
                165                 170                 175     


Thr Val Pro Lys Leu Leu Ile Tyr Gly His Thr Asn Arg Pro Ala Gly 
            180                 185                 190         


Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu 
        195                 200                 205             


Ala Ile Ser Gly Phe Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala 
    210                 215                 220                 


Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys 
225                 230                 235                 240 


Leu Thr Val Leu Gly Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu 
                245                 250                 255     


Asp Leu Asn Gly Ala Ala His His His His His His 
            260                 265             


<210>  66
<211>  39
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for substituting the 
       N-terminal Gln residue with a Ser residue in AVP04-07

<400>  66
cccagccggc catggcgagc gtgcagctgc agcagagcg                              39


<210>  67
<211>  39
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for substituting the 
       N-terminal Gln residue with a Ser residue in AVP04-07

<400>  67
cgctctgctg cagctgcacg ctcgccatgg ccggctggg                              39


<210>  68
<211>  66
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 38 and 42 in the VL FR2 of 
       AVP04-07

<400>  68
cagaaaaact atctggcgtg gtatcagtgc aaaccgggtt gcagcccgaa actgctgatt       60

tattgg                                                                  66


<210>  69
<211>  66
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 38 and 42 in the VL FR2 of 
       AVP04-07

<400>  69
ccaataaatc agcagtttcg ggctgcaacc cggtttgcac tgataccacg ccagatagtt       60

tttctg                                                                  66


<210>  70
<211>  72
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 38 and 44 in the VL FR2 of 
       AVP04-07

<400>  70
cagaaaaact atctggcgtg gtatcagtgc aaaccgggtc agagctgcaa actgctgatt       60

tattgggcga gc                                                           72


<210>  71
<211>  72
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 38 and 44 in the VL FR2 of 
       AVP04-07

<400>  71
gctcgcccaa taaatcagca gtttgcagct ctgacccggt ttgcactgat accacgccag       60

atagtttttc tg                                                           72


<210>  72
<211>  65
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 78 and 82 in the VL FR3 of 
       AVP04-07

<400>  72
ccgattttac cctgagcatt agcagctgcg aaaccgaatg cctggcggtg tattattgcc       60

agcag                                                                   65


<210>  73
<211>  65
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 78 and 82 in the VL FR3 of 
       AVP04-07

<400>  73
ctgctggcaa taatacaccg ccaggcattc ggtttcgcag ctgctaatgc tcagggtaaa       60

atcgg                                                                   65


<210>  74
<211>  67
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 39 and 43 in the VH FR2 of 
       AVP04-07

<400>  74
cgatcatgcg attcattggg tgaaatgcaa tccggaatgc ggcctggaat ggattggcta       60

ttttagc                                                                 67


<210>  75
<211>  67
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 39 and 43 in the VH FR2 of 
       AVP04-07

<400>  75
gctaaaatag ccaatccatt ccaggccgca ttccggattg catttcaccc aatgaatcgc       60

atgatcg                                                                 67


<210>  76
<211>  70
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 39 and 45 in the VH FR2 of 
       AVP04-07

<400>  76
cgatcatgcg attcattggg tgaaatgcaa tccggaacag ggctgcgaat ggattggcta       60

ttttagcccg                                                              70


<210>  77
<211>  70
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 39 and 45 in the VH FR2 of 
       AVP04-07

<400>  77
cgggctaaaa tagccaatcc attcgcagcc ctgttccgga ttgcatttca cccaatgaat       60

cgcatgatcg                                                              70


<210>  78
<211>  58
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 82C and 86 in the VH FR3 of 
       AVP04-07

<400>  78
gcgtatctgc agctgaacag ctgcaccagc gaatgcagcg cggtgtattt ttgcaccc         58


<210>  79
<211>  58
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 82C and 86 in the VH FR3 of 
       AVP04-07

<400>  79
gggtgcaaaa atacaccgcg ctgcattcgc tggtgcagct gttcagctgc agatacgc         58


<210>  80
<211>  60
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 70 and 79 in the VH FR3 of 
       AVP04-07

<400>  80
ggcaaagcga ccctgtgcgc ggataaaagc agcagcaccg cgtgcctgca gctgaacagc       60


<210>  81
<211>  56
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 70 and 79 in the VH FR3 of 
       AVP04-07

<400>  81
cgctgctaat gcacagggta aaatcggtgc cgctaccgct gccgcaaaaa cgatcc           56


<210>  82
<211>  54
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 72 and 75 in the VH FR3 of 
       AVP04-07

<400>  82
ggcaaagcga ccctgaccgc gtgcaaaagc tgcagcaccg cgtatctgca gctg             54


<210>  83
<211>  54
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 72 and 75 in the VH FR3 of 
       AVP04-07

<400>  83
cagctgcaga tacgcggtgc tgcagctttt gcacgcggtc agggtcgctt tgcc             54


<210>  84
<211>  48
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 65 and 72 in the VL FR3 of 
       AVP04-07

<400>  84
cgttttaccg gctgcggtag cggcaccgat ttttgcctga gcattagc                    48


<210>  85
<211>  48
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 65 and 72 in the VL FR3 of 
       AVP04-07

<400>  85
gctaatgctc aggcaaaaat cggtgccgct accgcagccg gtaaaacg                    48


<210>  86
<211>  50
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for modification of 
       linker residues of AVP04-79 for scFv expression

<400>  86
ctcggtcacc gtgagcagcg gtggcggcgg cagcggtggc ggcggcagcg                  50


<210>  87
<211>  50
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for modification of 
       linker residues of AVP04-79 for scFv expression

<400>  87
cgctgccgcc gccaccgctg ccgccgccac cgctgctcac ggtgaccgag                  50


<210>  88
<211>  42
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for modification of 
       linker residues of AVP04-79 for triabody expression

<400>  88
ggcacctcgg tcaccgtgag cgatatcgtg atgacccaga gc                          42


<210>  89
<211>  42
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for modification of 
       linker residues of AVP04-79 for triabody expression

<400>  89
gctctgggtc atcacgatat cgctcacggt gaccgaggtg cc                          42


<210>  90
<211>  39
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for AVP07-17 anti-HER2 
       diabody replacing CDR3H Cysteine residues with alanines 
       designated AVP07-86

<400>  90
cccagccggc catggcgagc gtgcagctgg tgcagtctg                              39


<210>  91
<211>  39
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for AVP07-17 anti-HER2 
       diabody replacing CDR3H Cysteine residues with alanines 
       designated AVP07-86

<400>  91
cagactgcac cagctgcacg ctcgccatgg ccggctggg                              39


<210>  92
<211>  66
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 38 and 42 in the VL FR2 of 
       AVP02-60

<400>  92
cgtgagctat atgcattggt atcagtgcaa accgggctgc gcgccgaaac gttggattta       60

tgatac                                                                  66


<210>  93
<211>  66
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 38 and 42 in the VL FR2 of 
       AVP02-60

<400>  93
gtatcataaa tccaacgttt cggcgcgcag cccggtttgc actgatacca atgcatatag       60

ctcacg                                                                  66


<210>  94
<211>  55
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 39 and 43 in the VH FR2 of 
       AVP02-60

<400>  94
ctatggcatg agctgggtgc gttgcgcgcc ggattgcggc ctggaactgg tggcg            55


<210>  95
<211>  55
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 39 and 43 in the VH FR2 of 
       AVP02-60

<400>  95
cgccaccagt tccaggccgc aatccggcgc gcaacgcacc cagctcatgc catag            55


<210>  96
<211>  65
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 38 and 42 in the VL FR2 of 
       AVP07-86

<400>  96
gggaataatt atgtatcctg gtaccagtgc ctcccaggat gcgtccccaa actcctcatc       60

tatgg                                                                   65


<210>  97
<211>  65
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 38 and 42 in the VL FR2 of 
       AVP07-86

<400>  97
ccatagatga ggagtttggg gacgcatcct gggaggcact ggtaccagga tacataatta       60

ttccc                                                                   65


<210>  98
<211>  51
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 39 and 43 in the VH FR2 of 
       AVP07-86

<400>  98
ggatcgcctg ggtgcgctgc atgcccgggt gcggcctgga gtacatgggg c                51


<210>  99
<211>  51
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of mutagenic primer for introducing cysteine 
       residue substitutions at positions 39 and 43 in the VH FR2 of 
       AVP07-86

<400>  99
gccccatgta ctccaggccg cacccgggca tgcagcgcac ccaggcgatc c                51


<210>  100
<211>  735
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 42 
       designated AVP04-79.

<400>  100
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag cccgagcagc ctgccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagt gcaaaccggg ttgcagcccg aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc agcggtagcg gcaccgattt taccctgagc      600

attagcagcg tggaaaccga agatctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc actcgagcac      720

caccaccacc accac                                                       735


<210>  101
<211>  245
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 42 
       designated AVP04-79.

<400>  101

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro 
        115                 120                 125             


Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Cys Lys Pro Gly Cys Ser Pro Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr Glu Asp 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  102
<211>  735
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 44 is 
       designated AVP04-80.

<400>  102
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag cccgagcagc ctgccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagt gcaaaccggg tcagagctgc aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc agcggtagcg gcaccgattt taccctgagc      600

attagcagcg tggaaaccga agatctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc actcgagcac      720

caccaccacc accac                                                       735


<210>  103
<211>  245
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 44 is 
       designated AVP04-80.

<400>  103

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro 
        115                 120                 125             


Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Cys Lys Pro Gly Gln Ser Cys Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr Glu Asp 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  104
<211>  735
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VL FR3 Kabat positions 78 and 82 
       designated AVP04-83.

<400>  104
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag cccgagcagc ctgccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagc agaaaccggg tcagagcccg aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc agcggtagcg gcaccgattt taccctgagc      600

attagcagct gcgaaaccga atgcctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc actcgagcac      720

caccaccacc accac                                                       735


<210>  105
<211>  245
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VL FR3 Kabat positions 78 and 82 
       designated AVP04-83.

<400>  105

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Ala Gly Ser Asp Ile Val Met Thr Gln Ser Pro 
        115                 120                 125             


Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Cys Glu Thr Glu Cys 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  106
<211>  735
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 43 
       designated AVP04-111.

<400>  106
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaatgcaat      120

ccggaatgcg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag cccgagcagc ctgccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagc agaaaccggg tcagagcccg aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc agcggtagcg gcaccgattt taccctgagc      600

attagcagcg tggaaaccga agatctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc actcgagcac      720

caccaccacc accac                                                       735


<210>  107
<211>  245
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 43 
       designated AVP04-111.

<400>  107

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Cys Asn Pro Glu Cys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro 
        115                 120                 125             


Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr Glu Asp 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  108
<211>  735
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 45 
       designated AVP04-112.

<400>  108
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaatgcaat      120

ccggaacagg gctgcgaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag cccgagcagc ctgccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagc agaaaccggg tcagagcccg aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc agcggtagcg gcaccgattt taccctgagc      600

attagcagcg tggaaaccga agatctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc actcgagcac      720

caccaccacc accac                                                       735


<210>  109
<211>  245
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 45 
       designated AVP04-112.

<400>  109

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Cys Asn Pro Glu Gln Gly Cys Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro 
        115                 120                 125             


Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr Glu Asp 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  110
<211>  735
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 82C and 86 
       designated AVP04-114

<400>  110
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagctgcac cagcgaatgc agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag cccgagcagc ctgccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagc agaaaccggg tcagagcccg aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc agcggtagcg gcaccgattt taccctgagc      600

attagcagcg tggaaaccga agatctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc actcgagcac      720

caccaccacc accac                                                       735


<210>  111
<211>  245
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 82C and 86 
       designated AVP04-114.

<400>  111

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Cys Thr Ser Glu Cys Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro 
        115                 120                 125             


Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr Glu Asp 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  112
<211>  735
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 70 and 79 
       designated AVP04-120

<400>  112
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg tgcgcggata aaagcagcag caccgcgtgc      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag cccgagcagc ctgccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagc agaaaccggg tcagagcccg aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc agcggtagcg gcaccgattt taccctgagc      600

attagcagcg tggaaaccga agatctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc actcgagcac      720

caccaccacc accac                                                       735


<210>  113
<211>  245
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 70 and 79 
       designated AVP04-120

<400>  113

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Cys Ala Asp Lys Ser Ser Ser Thr Ala Cys 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro 
        115                 120                 125             


Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr Glu Asp 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  114
<211>  735
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 72 and 75 
       designated AVP04-121

<400>  114
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcgtgca aaagctgcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag cccgagcagc ctgccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagc agaaaccggg tcagagcccg aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc agcggtagcg gcaccgattt taccctgagc      600

attagcagcg tggaaaccga agatctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc actcgagcac      720

caccaccacc accac                                                       735


<210>  115
<211>  245
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 72 and 75 
       designated AVP04-121

<400>  115

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Cys Lys Ser Cys Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro 
        115                 120                 125             


Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr Glu Asp 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  116
<211>  735
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VL FR3 Kabat positions 65 and 72 
       designated AVP04-123.

<400>  116
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag cccgagcagc ctgccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagc agaaaccggg tcagagcccg aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc tgcggtagcg gcaccgattt ttgcctgagc      600

attagcagcg tggaaaccga agatctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc actcgagcac      720

caccaccacc accac                                                       735


<210>  117
<211>  245
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 diabody comprising cysteine 
       replacement mutations in the VL FR3 Kabat positions 65 and 72 
       designated AVP04-123.

<400>  117

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro 
        115                 120                 125             


Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Cys Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Cys Leu Ser Ile Ser Ser Val Glu Thr Glu Asp 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  118
<211>  765
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 scFv comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 42 
       designated AVP04-124

<400>  118
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

ggtggcggcg gcagcggtgg cggcggcagc gatatcgtga tgacccagag cccgagcagc      420

ctgccggtga gcgtgggcga aaaagtgacc ctgagctgca aaagcagcca gagcctgctg      480

tatagcggca atcagaaaaa ctatctggcg tggtatcagt gcaaaccggg ttgcagcccg      540

aaactgctga tttattgggc gagcacccgt gaaagcggcg tgccggatcg ttttaccggc      600

agcggtagcg gcaccgattt taccctgagc attagcagcg tggaaaccga agatctggcg      660

gtgtattatt gccagcagta ttatagctat ccgctgacct ttggtgcggg caccaaactg      720

gtgctgaaac gtgcggccgc actcgagcac caccaccacc accac                      765


<210>  119
<211>  260
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 scFv comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 42 
       designated AVP04-124.

<400>  119

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
        115                 120                 125             


Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Ser 
    130                 135                 140                 


Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys Ser 
145                 150                 155                 160 


Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala Trp 
                165                 170                 175     


Tyr Gln Cys Lys Pro Gly Cys Ser Pro Lys Leu Leu Ile Tyr Trp Ala 
            180                 185                 190         


Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser 
        195                 200                 205             


Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr Glu Asp Leu 
    210                 215                 220                 


Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly 
225                 230                 235                 240 


Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His His 
                245                 250                 255     


His His His His 
            260 


<210>  120
<211>  717
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-TAG72 triabody comprising cysteine
       replacement mutations in the VL FR2 Kabat positions 38 and 42 
       designated AVP04-125.

<400>  120
caggtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcgatatcgt gatgacccag      360

agcccgagca gcctgccggt gagcgtgggc gaaaaagtga ccctgagctg caaaagcagc      420

cagagcctgc tgtatagcgg caatcagaaa aactatctgg cgtggtatca gtgcaaaccg      480

ggttgcagcc cgaaactgct gatttattgg gcgagcaccc gtgaaagcgg cgtgccggat      540

cgttttaccg gcagcggtag cggcaccgat tttaccctga gcattagcag cgtggaaacc      600

gaagatctgg cggtgtatta ttgccagcag tattatagct atccgctgac ctttggtgcg      660

ggcaccaaac tggtgctgaa acgtgcggcc gcactcgagc accaccacca ccaccac         717


<210>  121
<211>  239
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-TAG72 triabody comprising cysteine
       replacement mutations in the VL FR2 Kabat positions 38 and 42 
       designated AVP04-125

<400>  121

Gln Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Pro Val Ser 
        115                 120                 125             


Val Gly Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu 
    130                 135                 140                 


Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Cys Lys Pro 
145                 150                 155                 160 


Gly Cys Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser 
                165                 170                 175     


Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr 
            180                 185                 190         


Leu Ser Ile Ser Ser Val Glu Thr Glu Asp Leu Ala Val Tyr Tyr Cys 
        195                 200                 205             


Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu 
    210                 215                 220                 


Val Leu Lys Arg Ala Ala Ala Leu Glu His His His His His His 
225                 230                 235                 


<210>  122
<211>  729
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 42 
       designated AVP02-115

<400>  122
agcgtgcagc tggttgaaag cggtggcgga gtggtgcagc caggtggaag cctgcgtctg       60

agctgcgcag caagcggttt tacctttagc agctatggca tgagctgggt gcgtcaggcg      120

ccggataaag gcctggaact ggtggcgacc attaacagca acggtggaag cacctattat      180

ccggatagcg tgaaaggccg ttttaccatt agccgtgata acagcaaaaa caccctgtat      240

ctgcagatga acagcctgcg taccgaagat accgcggtgt attattgcgc gcgtgatcgt      300

gatggctatg atgaaggctt tgattattgg ggccagggca ccctggtgac cgtgagcagc      360

ggtgggggcg gaagccagat tcagctgacc cagagcccga gcagcctgag cgcaagcgtg      420

ggtgatcgtg tgaccattac ctgcagcgcg agcagcagcg tgagctatat gcattggtat      480

cagtgcaaac cgggctgcgc gccgaaacgt tggatttatg ataccagcaa actggcgagc      540

ggcgtgccga gccgttttag cggcagcggc agcggcaccg attatacctt taccattagc      600

agcctgcagc cggaagatat tgcgacctat tattgccagc agtggagcag caacccgccg      660

acctttggcc agggcaccaa actgcagatt aaacgtgcgg ccgcactcga gcaccaccac      720

caccaccac                                                              729


<210>  123
<211>  243
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 42 
       designated AVP02-115

<400>  123

Ser Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Ala Pro Asp Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Thr Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Asp Gly Tyr Asp Glu Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Ile Gln 
        115                 120                 125             


Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val 
    130                 135                 140                 


Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr 
145                 150                 155                 160 


Gln Cys Lys Pro Gly Cys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser 
                165                 170                 175     


Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
            180                 185                 190         


Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala 
        195                 200                 205             


Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr Phe Gly Gln 
    210                 215                 220                 


Gly Thr Lys Leu Gln Ile Lys Arg Ala Ala Ala Leu Glu His His His 
225                 230                 235                 240 


His His His 
            


<210>  124
<211>  729
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 43 
       designated AVP02-116.

<400>  124
agcgtgcagc tggttgaaag cggtggcgga gtggtgcagc caggtggaag cctgcgtctg       60

agctgcgcag caagcggttt tacctttagc agctatggca tgagctgggt gcgttgcgcg      120

ccggattgcg gcctggaact ggtggcgacc attaacagca acggtggaag cacctattat      180

ccggatagcg tgaaaggccg ttttaccatt agccgtgata acagcaaaaa caccctgtat      240

ctgcagatga acagcctgcg taccgaagat accgcggtgt attattgcgc gcgtgatcgt      300

gatggctatg atgaaggctt tgattattgg ggccagggca ccctggtgac cgtgagcagc      360

ggtgggggcg gaagccagat tcagctgacc cagagcccga gcagcctgag cgcaagcgtg      420

ggtgatcgtg tgaccattac ctgcagcgcg agcagcagcg tgagctatat gcattggtat      480

cagcagaaac cgggcaaagc gccgaaacgt tggatttatg ataccagcaa actggcgagc      540

ggcgtgccga gccgttttag cggcagcggc agcggcaccg attatacctt taccattagc      600

agcctgcagc cggaagatat tgcgacctat tattgccagc agtggagcag caacccgccg      660

acctttggcc agggcaccaa actgcagatt aaacgtgcgg ccgcactcga gcaccaccac      720

caccaccac                                                              729


<210>  125
<211>  243
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 43 
       designated AVP02-116.

<400>  125

Ser Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Cys Ala Pro Asp Cys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Thr Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Asp Gly Tyr Asp Glu Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Ile Gln 
        115                 120                 125             


Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val 
    130                 135                 140                 


Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr 
145                 150                 155                 160 


Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser 
                165                 170                 175     


Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
            180                 185                 190         


Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala 
        195                 200                 205             


Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr Phe Gly Gln 
    210                 215                 220                 


Gly Thr Lys Leu Gln Ile Lys Arg Ala Ala Ala Leu Glu His His His 
225                 230                 235                 240 


His His His 
            


<210>  126
<211>  804
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 42 
       designated AVP07-117.

<400>  126
agcgtgcagc tggtgcagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc       60

tcctgtaagg gttctggata cagctttacc agctactgga tcgcctgggt gcgccagatg      120

cccgggaaag gcctggagta catggggctc atctatcctg gtgactctga caccaaatac      180

agcccgtcct tccaaggcca ggtcaccatc tcagtcgaca agtccgtcag cactgcctac      240

ttgcaatgga gcagtctgaa gccctcggac agcgccgtgt atttttgtgc gagacatgac      300

gtgggatatg cgagtagttc caacgcggca aagtggcctg aatacttcca gcattggggc      360

cagggcaccc tggtcaccgt ttcctcaggt ggaggcggtt cacagtctgt gttgacgcag      420

ccgccctcag tgtctgcggc cccaggacag aaggtcacca tctcctgctc tggaagcagc      480

tccaacattg ggaataatta tgtatcctgg taccagtgcc tcccaggatg cgtccccaaa      540

ctcctcatct atggtcacac caatcggccc gcaggggtcc ctgaccgatt ctctggctcc      600

aagtctggca cctcagcctc cctggccatc agtgggttcc ggtccgagga tgaggctgat      660

tattactgtg cagcatggga tgacagcctg agtggttggg tgttcggcgg agggaccaag      720

ctgaccgtcc taggtgcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg      780

gccgcacatc accatcatca ccat                                             804


<210>  127
<211>  268
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 42 
       designated AVP07-117.

<400>  127

Ser Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Tyr Met 
        35                  40                  45              


Gly Leu Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Pro Ser Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Asp Val Gly Tyr Ala Ser Ser Ser Asn Ala Ala Lys Trp 
            100                 105                 110         


Pro Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val 
    130                 135                 140                 


Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser 
145                 150                 155                 160 


Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Cys Leu Pro Gly 
                165                 170                 175     


Cys Val Pro Lys Leu Leu Ile Tyr Gly His Thr Asn Arg Pro Ala Gly 
            180                 185                 190         


Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu 
        195                 200                 205             


Ala Ile Ser Gly Phe Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala 
    210                 215                 220                 


Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys 
225                 230                 235                 240 


Leu Thr Val Leu Gly Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu 
                245                 250                 255     


Asp Leu Asn Gly Ala Ala His His His His His His 
            260                 265             


<210>  128
<211>  804
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 43 
       designated AVP07-118.

<400>  128
agcgtgcagc tggtgcagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc       60

tcctgtaagg gttctggata cagctttacc agctactgga tcgcctgggt gcgctgcatg      120

cccgggtgcg gcctggagta catggggctc atctatcctg gtgactctga caccaaatac      180

agcccgtcct tccaaggcca ggtcaccatc tcagtcgaca agtccgtcag cactgcctac      240

ttgcaatgga gcagtctgaa gccctcggac agcgccgtgt atttttgtgc gagacatgac      300

gtgggatatg cgagtagttc caacgcggca aagtggcctg aatacttcca gcattggggc      360

cagggcaccc tggtcaccgt ttcctcaggt ggaggcggtt cacagtctgt gttgacgcag      420

ccgccctcag tgtctgcggc cccaggacag aaggtcacca tctcctgctc tggaagcagc      480

tccaacattg ggaataatta tgtatcctgg taccagcagc tcccaggaac agtccccaaa      540

ctcctcatct atggtcacac caatcggccc gcaggggtcc ctgaccgatt ctctggctcc      600

aagtctggca cctcagcctc cctggccatc agtgggttcc ggtccgagga tgaggctgat      660

tattactgtg cagcatggga tgacagcctg agtggttggg tgttcggcgg agggaccaag      720

ctgaccgtcc taggtgcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg      780

gccgcacatc accatcatca ccat                                             804


<210>  129
<211>  268
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 43 
       designated AVP07-118.

<400>  129

Ser Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Cys Met Pro Gly Cys Gly Leu Glu Tyr Met 
        35                  40                  45              


Gly Leu Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Pro Ser Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Asp Val Gly Tyr Ala Ser Ser Ser Asn Ala Ala Lys Trp 
            100                 105                 110         


Pro Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val 
    130                 135                 140                 


Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser 
145                 150                 155                 160 


Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly 
                165                 170                 175     


Thr Val Pro Lys Leu Leu Ile Tyr Gly His Thr Asn Arg Pro Ala Gly 
            180                 185                 190         


Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu 
        195                 200                 205             


Ala Ile Ser Gly Phe Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala 
    210                 215                 220                 


Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys 
225                 230                 235                 240 


Leu Thr Val Leu Gly Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu 
                245                 250                 255     


Asp Leu Asn Gly Ala Ala His His His His His His 
            260                 265             


<210>  130
<211>  729
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 44 
       designated AVP02-126

<400>  130
agcgtgcagc tggttgaaag cggtggcgga gtggtgcagc caggtggaag cctgcgtctg       60

agctgcgcag caagcggttt tacctttagc agctatggca tgagctgggt gcgtcaggcg      120

ccggataaag gcctggaact ggtggcgacc attaacagca acggtggaag cacctattat      180

ccggatagcg tgaaaggccg ttttaccatt agccgtgata acagcaaaaa caccctgtat      240

ctgcagatga acagcctgcg taccgaagat accgcggtgt attattgcgc gcgtgatcgt      300

gatggctatg atgaaggctt tgattattgg ggccagggca ccctggtgac cgtgagcagc      360

ggtgggggcg gaagccagat tcagctgacc cagagcccga gcagcctgag cgcaagcgtg      420

ggtgatcgtg tgaccattac ctgcagcgcg agcagcagcg tgagctatat gcattggtat      480

cagtgcaaac cgggcaaagc gtgcaaacgt tggatttatg ataccagcaa actggcgagc      540

ggcgtgccga gccgttttag cggcagcggc agcggcaccg attatacctt taccattagc      600

agcctgcagc cggaagatat tgcgacctat tattgccagc agtggagcag caacccgccg      660

acctttggcc agggcaccaa actgcagatt aaacgtgcgg ccgcactcga gcaccaccac      720

caccaccac                                                              729


<210>  131
<211>  243
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 44 
       designated AVP02-126.

<400>  131

Ser Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Ala Pro Asp Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Thr Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Asp Gly Tyr Asp Glu Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Ile Gln 
        115                 120                 125             


Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val 
    130                 135                 140                 


Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr 
145                 150                 155                 160 


Gln Cys Lys Pro Gly Lys Ala Cys Lys Arg Trp Ile Tyr Asp Thr Ser 
                165                 170                 175     


Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
            180                 185                 190         


Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala 
        195                 200                 205             


Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr Phe Gly Gln 
    210                 215                 220                 


Gly Thr Lys Leu Gln Ile Lys Arg Ala Ala Ala Leu Glu His His His 
225                 230                 235                 240 


His His His 
            


<210>  132
<211>  729
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 45 
       designated AVP02-127

<400>  132
agcgtgcagc tggttgaaag cggtggcgga gtggtgcagc caggtggaag cctgcgtctg       60

agctgcgcag caagcggttt tacctttagc agctatggca tgagctgggt gcgttgcgcg      120

ccggataaag gctgcgaact ggtggcgacc attaacagca acggtggaag cacctattat      180

ccggatagcg tgaaaggccg ttttaccatt agccgtgata acagcaaaaa caccctgtat      240

ctgcagatga acagcctgcg taccgaagat accgcggtgt attattgcgc gcgtgatcgt      300

gatggctatg atgaaggctt tgattattgg ggccagggca ccctggtgac cgtgagcagc      360

ggtgggggcg gaagccagat tcagctgacc cagagcccga gcagcctgag cgcaagcgtg      420

ggtgatcgtg tgaccattac ctgcagcgcg agcagcagcg tgagctatat gcattggtat      480

cagcagaaac cgggcaaagc gccgaaacgt tggatttatg ataccagcaa actggcgagc      540

ggcgtgccga gccgttttag cggcagcggc agcggcaccg attatacctt taccattagc      600

agcctgcagc cggaagatat tgcgacctat tattgccagc agtggagcag caacccgccg      660

acctttggcc agggcaccaa actgcagatt aaacgtgcgg ccgcactcga gcaccaccac      720

caccaccac                                                              729


<210>  133
<211>  243
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 45 
       designated AVP02-127.

<400>  133

Ser Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Cys Ala Pro Asp Lys Gly Cys Glu Leu Val 
        35                  40                  45              


Ala Thr Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Asp Gly Tyr Asp Glu Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Ile Gln 
        115                 120                 125             


Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val 
    130                 135                 140                 


Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr 
145                 150                 155                 160 


Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser 
                165                 170                 175     


Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
            180                 185                 190         


Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala 
        195                 200                 205             


Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr Phe Gly Gln 
    210                 215                 220                 


Gly Thr Lys Leu Gln Ile Lys Arg Ala Ala Ala Leu Glu His His His 
225                 230                 235                 240 


His His His 
            


<210>  134
<211>  729
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VL FR3 Kabat positions 65 and 72 
       designated AVP02-128

<400>  134
agcgtgcagc tggttgaaag cggtggcgga gtggtgcagc caggtggaag cctgcgtctg       60

agctgcgcag caagcggttt tacctttagc agctatggca tgagctgggt gcgtcaggcg      120

ccggataaag gcctggaact ggtggcgacc attaacagca acggtggaag cacctattat      180

ccggatagcg tgaaaggccg ttttaccatt agccgtgata acagcaaaaa caccctgtat      240

ctgcagatga acagcctgcg taccgaagat accgcggtgt attattgcgc gcgtgatcgt      300

gatggctatg atgaaggctt tgattattgg ggccagggca ccctggtgac cgtgagcagc      360

ggtgggggcg gaagccagat tcagctgacc cagagcccga gcagcctgag cgcaagcgtg      420

ggtgatcgtg tgaccattac ctgcagcgcg agcagcagcg tgagctatat gcattggtat      480

cagcagaaac cgggcaaagc gccgaaacgt tggatttatg ataccagcaa actggcgagc      540

ggcgtgccga gccgttttag cggctgcggc agcggcaccg attattgctt taccattagc      600

agcctgcagc cggaagatat tgcgacctat tattgccagc agtggagcag caacccgccg      660

acctttggcc agggcaccaa actgcagatt aaacgtgcgg ccgcactcga gcaccaccac      720

caccaccac                                                              729


<210>  135
<211>  243
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VL FR3 Kabat positions 65 and 72 
       designated AVP02-128.

<400>  135

Ser Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Ala Pro Asp Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Thr Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Asp Gly Tyr Asp Glu Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Ile Gln 
        115                 120                 125             


Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val 
    130                 135                 140                 


Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr 
145                 150                 155                 160 


Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser 
                165                 170                 175     


Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Cys Gly Ser Gly 
            180                 185                 190         


Thr Asp Tyr Cys Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala 
        195                 200                 205             


Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr Phe Gly Gln 
    210                 215                 220                 


Gly Thr Lys Leu Gln Ile Lys Arg Ala Ala Ala Leu Glu His His His 
225                 230                 235                 240 


His His His 
            


<210>  136
<211>  729
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 70 and 79 
       designated AVP02-129.

<400>  136
agcgtgcagc tggttgaaag cggtggcgga gtggtgcagc caggtggaag cctgcgtctg       60

agctgcgcag caagcggttt tacctttagc agctatggca tgagctgggt gcgtcaggcg      120

ccggataaag gcctggaact ggtggcgacc attaacagca acggtggaag cacctattat      180

ccggatagcg tgaaaggccg ttttaccatt tgccgtgata acagcaaaaa caccctgtgc      240

ctgcagatga acagcctgcg taccgaagat accgcggtgt attattgcgc gcgtgatcgt      300

gatggctatg atgaaggctt tgattattgg ggccagggca ccctggtgac cgtgagcagc      360

ggtgggggcg gaagccagat tcagctgacc cagagcccga gcagcctgag cgcaagcgtg      420

ggtgatcgtg tgaccattac ctgcagcgcg agcagcagcg tgagctatat gcattggtat      480

cagcagaaac cgggcaaagc gccgaaacgt tggatttatg ataccagcaa actggcgagc      540

ggcgtgccga gccgttttag cggcagcggc agcggcaccg attatacctt taccattagc      600

agcctgcagc cggaagatat tgcgacctat tattgccagc agtggagcag caacccgccg      660

acctttggcc agggcaccaa actgcagatt aaacgtgcgg ccgcactcga gcaccaccac      720

caccaccac                                                              729


<210>  137
<211>  243
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 70 and 79 
       designated AVP02-129

<400>  137

Ser Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Ala Pro Asp Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Thr Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Cys Arg Asp Asn Ser Lys Asn Thr Leu Cys 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Asp Gly Tyr Asp Glu Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Ile Gln 
        115                 120                 125             


Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val 
    130                 135                 140                 


Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr 
145                 150                 155                 160 


Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser 
                165                 170                 175     


Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
            180                 185                 190         


Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala 
        195                 200                 205             


Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr Phe Gly Gln 
    210                 215                 220                 


Gly Thr Lys Leu Gln Ile Lys Arg Ala Ala Ala Leu Glu His His His 
225                 230                 235                 240 


His His His 
            


<210>  138
<211>  729
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 72 and 75 
       designated AVP02-130

<400>  138
agcgtgcagc tggttgaaag cggtggcgga gtggtgcagc caggtggaag cctgcgtctg       60

agctgcgcag caagcggttt tacctttagc agctatggca tgagctgggt gcgtcaggcg      120

ccggataaag gcctggaact ggtggcgacc attaacagca acggtggaag cacctattat      180

ccggatagcg tgaaaggccg ttttaccatt agccgttgca acagctgcaa caccctgtat      240

ctgcagatga acagcctgcg taccgaagat accgcggtgt attattgcgc gcgtgatcgt      300

gatggctatg atgaaggctt tgattattgg ggccagggca ccctggtgac cgtgagcagc      360

ggtgggggcg gaagccagat tcagctgacc cagagcccga gcagcctgag cgcaagcgtg      420

ggtgatcgtg tgaccattac ctgcagcgcg agcagcagcg tgagctatat gcattggtat      480

cagcagaaac cgggcaaagc gccgaaacgt tggatttatg ataccagcaa actggcgagc      540

ggcgtgccga gccgttttag cggcagcggc agcggcaccg attatacctt taccattagc      600

agcctgcagc cggaagatat tgcgacctat tattgccagc agtggagcag caacccgccg      660

acctttggcc agggcaccaa actgcagatt aaacgtgcgg ccgcactcga gcaccaccac      720

caccaccac                                                              729


<210>  139
<211>  243
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-MucI diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 72 and 75 
       designated AVP02-130.

<400>  139

Ser Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Ala Pro Asp Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Thr Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Cys Asn Ser Cys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Asp Gly Tyr Asp Glu Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Ile Gln 
        115                 120                 125             


Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val 
    130                 135                 140                 


Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr 
145                 150                 155                 160 


Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser 
                165                 170                 175     


Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
            180                 185                 190         


Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala 
        195                 200                 205             


Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr Phe Gly Gln 
    210                 215                 220                 


Gly Thr Lys Leu Gln Ile Lys Arg Ala Ala Ala Leu Glu His His His 
225                 230                 235                 240 


His His His 
            


<210>  140
<211>  804
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-Her2 diabody comprising cysteine 

       replacement mutations in the VL FR2 Kabat positions 38 and 44 
       designated AVP07-131.

<400>  140
agcgtgcagc tggtgcagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc       60

tcctgtaagg gttctggata cagctttacc agctactgga tcgcctgggt gcgccagatg      120

cccgggaaag gcctggagta catggggctc atctatcctg gtgactctga caccaaatac      180

agcccgtcct tccaaggcca ggtcaccatc tcagtcgaca agtccgtcag cactgcctac      240

ttgcaatgga gcagtctgaa gccctcggac agcgccgtgt atttttgtgc gagacatgac      300

gtgggatatg cgagtagttc caacgcggca aagtggcctg aatacttcca gcattggggc      360

cagggcaccc tggtcaccgt ttcctcaggt ggaggcggtt cacagtctgt gttgacgcag      420

ccgccctcag tgtctgcggc cccaggacag aaggtcacca tctcctgctc tggaagcagc      480

tccaacattg ggaataatta tgtatcctgg taccagtgcc tcccaggaac agtctgcaaa      540

ctcctcatct atggtcacac caatcggccc gcaggggtcc ctgaccgatt ctctggctcc      600

aagtctggca cctcagcctc cctggccatc agtgggttcc ggtccgagga tgaggctgat      660

tattactgtg cagcatggga tgacagcctg agtggttggg tgttcggcgg agggaccaag      720

ctgaccgtcc taggtgcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg      780

gccgcacatc accatcatca ccat                                             804


<210>  141
<211>  268
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VL FR2 Kabat positions 38 and 44 
       designated AVP07-131.

<400>  141

Ser Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Tyr Met 
        35                  40                  45              


Gly Leu Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Pro Ser Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Asp Val Gly Tyr Ala Ser Ser Ser Asn Ala Ala Lys Trp 
            100                 105                 110         


Pro Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val 
    130                 135                 140                 


Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser 
145                 150                 155                 160 


Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Cys Leu Pro Gly 
                165                 170                 175     


Thr Val Cys Lys Leu Leu Ile Tyr Gly His Thr Asn Arg Pro Ala Gly 
            180                 185                 190         


Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu 
        195                 200                 205             


Ala Ile Ser Gly Phe Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala 
    210                 215                 220                 


Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys 
225                 230                 235                 240 


Leu Thr Val Leu Gly Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu 
                245                 250                 255     


Asp Leu Asn Gly Ala Ala His His His His His His 
            260                 265             


<210>  142
<211>  804
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 45 
       designated AVP07-132.

<400>  142
agcgtgcagc tggtgcagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc       60

tcctgtaagg gttctggata cagctttacc agctactgga tcgcctgggt gcgctgcatg      120

cccgggaaag gctgcgagta catggggctc atctatcctg gtgactctga caccaaatac      180

agcccgtcct tccaaggcca ggtcaccatc tcagtcgaca agtccgtcag cactgcctac      240

ttgcaatgga gcagtctgaa gccctcggac agcgccgtgt atttttgtgc gagacatgac      300

gtgggatatg cgagtagttc caacgcggca aagtggcctg aatacttcca gcattggggc      360

cagggcaccc tggtcaccgt ttcctcaggt ggaggcggtt cacagtctgt gttgacgcag      420

ccgccctcag tgtctgcggc cccaggacag aaggtcacca tctcctgctc tggaagcagc      480

tccaacattg ggaataatta tgtatcctgg taccagcagc tcccaggaac agtccccaaa      540

ctcctcatct atggtcacac caatcggccc gcaggggtcc ctgaccgatt ctctggctcc      600

aagtctggca cctcagcctc cctggccatc agtgggttcc ggtccgagga tgaggctgat      660

tattactgtg cagcatggga tgacagcctg agtggttggg tgttcggcgg agggaccaag      720

ctgaccgtcc taggtgcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg      780

gccgcacatc accatcatca ccat                                             804


<210>  143
<211>  268
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VH FR2 Kabat positions 39 and 45 
       designated AVP07-132.

<400>  143

Ser Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Cys Met Pro Gly Lys Gly Cys Glu Tyr Met 
        35                  40                  45              


Gly Leu Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Pro Ser Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Asp Val Gly Tyr Ala Ser Ser Ser Asn Ala Ala Lys Trp 
            100                 105                 110         


Pro Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val 
    130                 135                 140                 


Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser 
145                 150                 155                 160 


Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly 
                165                 170                 175     


Thr Val Pro Lys Leu Leu Ile Tyr Gly His Thr Asn Arg Pro Ala Gly 
            180                 185                 190         


Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu 
        195                 200                 205             


Ala Ile Ser Gly Phe Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala 
    210                 215                 220                 


Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys 
225                 230                 235                 240 


Leu Thr Val Leu Gly Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu 
                245                 250                 255     


Asp Leu Asn Gly Ala Ala His His His His His His 
            260                 265             


<210>  144
<211>  804
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-Her2 diabody comprising cysteine 

       replacement mutations in the VL FR3 Kabat positions 65 and 72 
       designated AVP07-133.

<400>  144
agcgtgcagc tggtgcagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc       60

tcctgtaagg gttctggata cagctttacc agctactgga tcgcctgggt gcgccagatg      120

cccgggaaag gcctggagta catggggctc atctatcctg gtgactctga caccaaatac      180

agcccgtcct tccaaggcca ggtcaccatc tcagtcgaca agtccgtcag cactgcctac      240

ttgcaatgga gcagtctgaa gccctcggac agcgccgtgt atttttgtgc gagacatgac      300

gtgggatatg cgagtagttc caacgcggca aagtggcctg aatacttcca gcattggggc      360

cagggcaccc tggtcaccgt ttcctcaggt ggaggcggtt cacagtctgt gttgacgcag      420

ccgccctcag tgtctgcggc cccaggacag aaggtcacca tctcctgctc tggaagcagc      480

tccaacattg ggaataatta tgtatcctgg taccagcagc tcccaggaac agtccccaaa      540

ctcctcatct atggtcacac caatcggccc gcaggggtcc ctgaccgatt ctctggctgc      600

aagtctggca cctcagcctg cctggccatc agtgggttcc ggtccgagga tgaggctgat      660

tattactgtg cagcatggga tgacagcctg agtggttggg tgttcggcgg agggaccaag      720

ctgaccgtcc taggtgcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg      780

gccgcacatc accatcatca ccat                                             804


<210>  145
<211>  268
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VL FR3 Kabat positions 65 and 72 
       designated AVP07-133.

<400>  145

Ser Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Tyr Met 
        35                  40                  45              


Gly Leu Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Pro Ser Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Asp Val Gly Tyr Ala Ser Ser Ser Asn Ala Ala Lys Trp 
            100                 105                 110         


Pro Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val 
    130                 135                 140                 


Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser 
145                 150                 155                 160 


Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly 
                165                 170                 175     


Thr Val Pro Lys Leu Leu Ile Tyr Gly His Thr Asn Arg Pro Ala Gly 
            180                 185                 190         


Val Pro Asp Arg Phe Ser Gly Cys Lys Ser Gly Thr Ser Ala Cys Leu 
        195                 200                 205             


Ala Ile Ser Gly Phe Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala 
    210                 215                 220                 


Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys 
225                 230                 235                 240 


Leu Thr Val Leu Gly Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu 
                245                 250                 255     


Asp Leu Asn Gly Ala Ala His His His His His His 
            260                 265             


<210>  146
<211>  804
<212>  DNA
<213>  Artificial

<220>
<223>  nucleotide sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 70 and 79 
       designated AVP07-134.

<400>  146
agcgtgcagc tggtgcagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc       60

tcctgtaagg gttctggata cagctttacc agctactgga tcgcctgggt gcgccagatg      120

cccgggaaag gcctggagta catggggctc atctatcctg gtgactctga caccaaatac      180

agcccgtcct tccaaggcca ggtcaccatc tgcgtcgaca agtccgtcag cactgcctgc      240

ttgcaatgga gcagtctgaa gccctcggac agcgccgtgt atttttgtgc gagacatgac      300

gtgggatatg cgagtagttc caacgcggca aagtggcctg aatacttcca gcattggggc      360

cagggcaccc tggtcaccgt ttcctcaggt ggaggcggtt cacagtctgt gttgacgcag      420

ccgccctcag tgtctgcggc cccaggacag aaggtcacca tctcctgctc tggaagcagc      480

tccaacattg ggaataatta tgtatcctgg taccagcagc tcccaggaac agtccccaaa      540

ctcctcatct atggtcacac caatcggccc gcaggggtcc ctgaccgatt ctctggctcc      600

aagtctggca cctcagcctc cctggccatc agtgggttcc ggtccgagga tgaggctgat      660

tattactgtg cagcatggga tgacagcctg agtggttggg tgttcggcgg agggaccaag      720

ctgaccgtcc taggtgcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg      780

gccgcacatc accatcatca ccat                                             804


<210>  147
<211>  268
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 70 and 79 
       designated AVP07-134

<400>  147

Ser Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Tyr Met 
        35                  40                  45              


Gly Leu Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Cys Val Asp Lys Ser Val Ser Thr Ala Cys 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Pro Ser Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Asp Val Gly Tyr Ala Ser Ser Ser Asn Ala Ala Lys Trp 
            100                 105                 110         


Pro Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val 
    130                 135                 140                 


Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser 
145                 150                 155                 160 


Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly 
                165                 170                 175     


Thr Val Pro Lys Leu Leu Ile Tyr Gly His Thr Asn Arg Pro Ala Gly 
            180                 185                 190         


Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu 
        195                 200                 205             


Ala Ile Ser Gly Phe Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala 
    210                 215                 220                 


Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys 
225                 230                 235                 240 


Leu Thr Val Leu Gly Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu 
                245                 250                 255     


Asp Leu Asn Gly Ala Ala His His His His His His 
            260                 265             


<210>  148
<211>  804
<212>  DNA
<213>  Artificial

<220>
<223>  SEQ ID NO: 148 - nucleotide sequence of an anti-Her2 diabody 
       comprising cysteine replacement mutations in the VH FR3 Kabat 
       positions 72 and 75 designated AVP07-135.

<400>  148
agcgtgcagc tggtgcagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc       60

tcctgtaagg gttctggata cagctttacc agctactgga tcgcctgggt gcgccagatg      120

cccgggaaag gcctggagta catggggctc atctatcctg gtgactctga caccaaatac      180

agcccgtcct tccaaggcca ggtcaccatc tcagtctgca agtcctgcag cactgcctac      240

ttgcaatgga gcagtctgaa gccctcggac agcgccgtgt atttttgtgc gagacatgac      300

gtgggatatg cgagtagttc caacgcggca aagtggcctg aatacttcca gcattggggc      360

cagggcaccc tggtcaccgt ttcctcaggt ggaggcggtt cacagtctgt gttgacgcag      420

ccgccctcag tgtctgcggc cccaggacag aaggtcacca tctcctgctc tggaagcagc      480

tccaacattg ggaataatta tgtatcctgg taccagcagc tcccaggaac agtccccaaa      540

ctcctcatct atggtcacac caatcggccc gcaggggtcc ctgaccgatt ctctggctcc      600

aagtctggca cctcagcctc cctggccatc agtgggttcc ggtccgagga tgaggctgat      660

tattactgtg cagcatggga tgacagcctg agtggttggg tgttcggcgg agggaccaag      720

ctgaccgtcc taggtgcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg      780

gccgcacatc accatcatca ccat                                             804


<210>  149
<211>  268
<212>  PRT
<213>  Artificial

<220>
<223>  amino acid sequence of an anti-Her2 diabody comprising cysteine 
       replacement mutations in the VH FR3 Kabat positions 72 and 75 
       designated AVP07-135.

<400>  149

Ser Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Tyr Met 
        35                  40                  45              


Gly Leu Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Val Cys Lys Ser Cys Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Pro Ser Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Asp Val Gly Tyr Ala Ser Ser Ser Asn Ala Ala Lys Trp 
            100                 105                 110         


Pro Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val 
    130                 135                 140                 


Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser 
145                 150                 155                 160 


Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly 
                165                 170                 175     


Thr Val Pro Lys Leu Leu Ile Tyr Gly His Thr Asn Arg Pro Ala Gly 
            180                 185                 190         


Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu 
        195                 200                 205             


Ala Ile Ser Gly Phe Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala 
    210                 215                 220                 


Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys 
225                 230                 235                 240 


Leu Thr Val Leu Gly Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu 
                245                 250                 255     


Asp Leu Asn Gly Ala Ala His His His His His His 
            260                 265             


<210>  150
<211>  1255
<212>  PRT
<213>  Homo sapiens

<400>  150

Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu 
1               5                   10                  15      


Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys 
            20                  25                  30          


Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His 
        35                  40                  45              


Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr 
    50                  55                  60                  


Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val 
65                  70                  75                  80  


Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu 
                85                  90                  95      


Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr 
            100                 105                 110         


Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro 
        115                 120                 125             


Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser 
    130                 135                 140                 


Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln 
145                 150                 155                 160 


Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn 
                165                 170                 175     


Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys 
            180                 185                 190         


His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser 
        195                 200                 205             


Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys 
    210                 215                 220                 


Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys 
225                 230                 235                 240 


Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu 
                245                 250                 255     


His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val 
            260                 265                 270         


Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg 
        275                 280                 285             


Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu 
    290                 295                 300                 


Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln 
305                 310                 315                 320 


Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys 
                325                 330                 335     


Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu 
            340                 345                 350         


Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys 
        355                 360                 365             


Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp 
    370                 375                 380                 


Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe 
385                 390                 395                 400 


Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro 
                405                 410                 415     


Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg 
            420                 425                 430         


Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu 
        435                 440                 445             


Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly 
    450                 455                 460                 


Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val 
465                 470                 475                 480 


Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr 
                485                 490                 495     


Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His 
            500                 505                 510         


Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys 
        515                 520                 525             


Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys 
    530                 535                 540                 


Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys 
545                 550                 555                 560 


Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys 
                565                 570                 575     


Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp 
            580                 585                 590         


Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu 
        595                 600                 605             


Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln 
    610                 615                 620                 


Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys 
625                 630                 635                 640 


Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Val Ser 
                645                 650                 655     


Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly 
            660                 665                 670         


Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg 
        675                 680                 685             


Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly 
    690                 695                 700                 


Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu 
705                 710                 715                 720 


Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys 
                725                 730                 735     


Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile 
            740                 745                 750         


Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu 
        755                 760                 765             


Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg 
    770                 775                 780                 


Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu 
785                 790                 795                 800 


Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg 
                805                 810                 815     


Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly 
            820                 825                 830         


Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala 
        835                 840                 845             


Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe 
    850                 855                 860                 


Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp 
865                 870                 875                 880 


Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg 
                885                 890                 895     


Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val 
            900                 905                 910         


Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala 
        915                 920                 925             


Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro 
    930                 935                 940                 


Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met 
945                 950                 955                 960 


Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe 
                965                 970                 975     


Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu 
            980                 985                 990         


Asp Leu Gly Pro Ala Ser Pro Leu  Asp Ser Thr Phe Tyr  Arg Ser Leu 
        995                 1000                 1005             


Leu Glu  Asp Asp Asp Met Gly  Asp Leu Val Asp Ala  Glu Glu Tyr 
    1010                 1015                 1020             


Leu Val  Pro Gln Gln Gly Phe  Phe Cys Pro Asp Pro  Ala Pro Gly 
    1025                 1030                 1035             


Ala Gly  Gly Met Val His His  Arg His Arg Ser Ser  Ser Thr Arg 
    1040                 1045                 1050             


Ser Gly  Gly Gly Asp Leu Thr  Leu Gly Leu Glu Pro  Ser Glu Glu 
    1055                 1060                 1065             


Glu Ala  Pro Arg Ser Pro Leu  Ala Pro Ser Glu Gly  Ala Gly Ser 
    1070                 1075                 1080             


Asp Val  Phe Asp Gly Asp Leu  Gly Met Gly Ala Ala  Lys Gly Leu 
    1085                 1090                 1095             


Gln Ser  Leu Pro Thr His Asp  Pro Ser Pro Leu Gln  Arg Tyr Ser 
    1100                 1105                 1110             


Glu Asp  Pro Thr Val Pro Leu  Pro Ser Glu Thr Asp  Gly Tyr Val 
    1115                 1120                 1125             


Ala Pro  Leu Thr Cys Ser Pro  Gln Pro Glu Tyr Val  Asn Gln Pro 
    1130                 1135                 1140             


Asp Val  Arg Pro Gln Pro Pro  Ser Pro Arg Glu Gly  Pro Leu Pro 
    1145                 1150                 1155             


Ala Ala  Arg Pro Ala Gly Ala  Thr Leu Glu Arg Ala  Lys Thr Leu 
    1160                 1165                 1170             


Ser Pro  Gly Lys Asn Gly Val  Val Lys Asp Val Phe  Ala Phe Gly 
    1175                 1180                 1185             


Gly Ala  Val Glu Asn Pro Glu  Tyr Leu Thr Pro Gln  Gly Gly Ala 
    1190                 1195                 1200             


Ala Pro  Gln Pro His Pro Pro  Pro Ala Phe Ser Pro  Ala Phe Asp 
    1205                 1210                 1215             


Asn Leu  Tyr Tyr Trp Asp Gln  Asp Pro Pro Glu Arg  Gly Ala Pro 
    1220                 1225                 1230             


Pro Ser  Thr Phe Lys Gly Thr  Pro Thr Ala Glu Asn  Pro Glu Tyr 
    1235                 1240                 1245             


Leu Gly  Leu Asp Val Pro Val  
    1250                 1255 


<210>  151
<211>  750
<212>  PRT
<213>  Homo sapiens

<400>  151

Met Trp Asn Leu Leu His Glu Thr Asp Ser Ala Val Ala Thr Ala Arg 
1               5                   10                  15      


Arg Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Phe 
            20                  25                  30          


Phe Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ser Asn Glu 
        35                  40                  45              


Ala Thr Asn Ile Thr Pro Lys His Asn Met Lys Ala Phe Leu Asp Glu 
    50                  55                  60                  


Leu Lys Ala Glu Asn Ile Lys Lys Phe Leu His Asn Phe Thr Gln Ile 
65                  70                  75                  80  


Pro His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile 
                85                  90                  95      


Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Ala His 
            100                 105                 110         


Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn Tyr Ile 
        115                 120                 125             


Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn Thr Ser Leu Phe 
    130                 135                 140                 


Glu Pro Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Ile Val Pro Pro 
145                 150                 155                 160 


Phe Ser Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr 
                165                 170                 175     


Val Asn Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met 
            180                 185                 190         


Lys Ile Asn Cys Ser Gly Lys Ile Val Ile Ala Arg Tyr Gly Lys Val 
        195                 200                 205             


Phe Arg Gly Asn Lys Val Lys Asn Ala Gln Leu Ala Gly Ala Lys Gly 
    210                 215                 220                 


Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val Lys 
225                 230                 235                 240 


Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly Val Gln Arg Gly 
                245                 250                 255     


Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu Thr Pro Gly Tyr 
            260                 265                 270         


Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala Glu Ala Val Gly 
        275                 280                 285             


Leu Pro Ser Ile Pro Val His Pro Ile Gly Tyr Tyr Asp Ala Gln Lys 
    290                 295                 300                 


Leu Leu Glu Lys Met Gly Gly Ser Ala Pro Pro Asp Ser Ser Trp Arg 
305                 310                 315                 320 


Gly Ser Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn 
                325                 330                 335     


Phe Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Asn Glu Val 
            340                 345                 350         


Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu Pro 
        355                 360                 365             


Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp Val Phe Gly 
    370                 375                 380                 


Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val His Glu Ile Val Arg 
385                 390                 395                 400 


Ser Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr Ile 
                405                 410                 415     


Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Gly Ser Thr 
            420                 425                 430         


Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln Glu Arg Gly Val Ala 
        435                 440                 445             


Tyr Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val 
    450                 455                 460                 


Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His Asn Leu Thr Lys Glu 
465                 470                 475                 480 


Leu Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser 
                485                 490                 495     


Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile 
            500                 505                 510         


Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu 
        515                 520                 525             


Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys Asn Trp Glu Thr Asn 
    530                 535                 540                 


Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val Tyr Glu Thr Tyr Glu 
545                 550                 555                 560 


Leu Val Glu Lys Phe Tyr Asp Pro Met Phe Lys Tyr His Leu Thr Val 
                565                 570                 575     


Ala Gln Val Arg Gly Gly Met Val Phe Glu Leu Ala Asn Ser Ile Val 
            580                 585                 590         


Leu Pro Phe Asp Cys Arg Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala 
        595                 600                 605             


Asp Lys Ile Tyr Ser Ile Ser Met Lys His Pro Gln Glu Met Lys Thr 
    610                 615                 620                 


Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr 
625                 630                 635                 640 


Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser 
                645                 650                 655     


Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu 
            660                 665                 670         


Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg 
        675                 680                 685             


His Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser 
    690                 695                 700                 


Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp 
705                 710                 715                 720 


Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala 
                725                 730                 735     


Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala 
            740                 745                 750 


<210>  152
<211>  475
<212>  PRT
<213>  Homo sapiens

<400>  152

Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr 
1               5                   10                  15      


Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly 
            20                  25                  30          


Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser 
        35                  40                  45              


Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His 
    50                  55                  60                  


Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu 
65                  70                  75                  80  


Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln 
                85                  90                  95      


Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr 
            100                 105                 110         


Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro 
        115                 120                 125             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    130                 135                 140                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
145                 150                 155                 160 


Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala Pro Pro Val His 
                165                 170                 175     


Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser Ala Ser Thr Leu 
            180                 185                 190         


Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr Pro Ala Ser Lys 
        195                 200                 205             


Ser Thr Pro Phe Ser Ile Pro Ser His His Ser Asp Thr Pro Thr Thr 
    210                 215                 220                 


Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser Thr His His Ser 
225                 230                 235                 240 


Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr Ser Pro Gln Leu 
                245                 250                 255     


Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu 
            260                 265                 270         


Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu 
        275                 280                 285             


Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln Gly 
    290                 295                 300                 


Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val 
305                 310                 315                 320 


Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp 
                325                 330                 335     


Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr 
            340                 345                 350         


Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe 
        355                 360                 365             


Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile Ala Leu Leu 
    370                 375                 380                 


Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr Leu Ile Ala 
385                 390                 395                 400 


Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu Asp Ile 
                405                 410                 415     


Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr Pro Thr Tyr 
            420                 425                 430         


His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp Arg Ser Pro 
        435                 440                 445             


Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu Ser Tyr Thr 
    450                 455                 460                 


Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu 
465                 470                 475 


<210>  153
<211>  307
<212>  PRT
<213>  Homo sapiens

<400>  153

Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr 
1               5                   10                  15      


Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly 
            20                  25                  30          


Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser 
        35                  40                  45              


Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His 
    50                  55                  60                  


Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu 
65                  70                  75                  80  


Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln 
                85                  90                  95      


Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr 
            100                 105                 110         


Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro 
        115                 120                 125             


Gly Ser Thr Ala Pro Pro Ala Gln Gly Val Thr Ser Ala Pro Glu Thr 
    130                 135                 140                 


Arg Pro Pro Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
145                 150                 155                 160 


Ala Pro Asp Asn Arg Pro Ala Leu Ala Ser Thr Ala Pro Pro Val His 
                165                 170                 175     


Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser Ala Ser Thr Leu 
            180                 185                 190         


Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr Pro Ala Ser Lys 
        195                 200                 205             


Ser Thr Pro Phe Ser Ile Pro Ser His His Ser Asp Thr Pro Thr Thr 
    210                 215                 220                 


Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser Thr His His Ser 
225                 230                 235                 240 


Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr Ser Pro Gln Leu 
                245                 250                 255     


Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu 
            260                 265                 270         


Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu 
        275                 280                 285             


Leu Gln Arg Asp Ile Ser Glu Met Val Ser Ile Gly Leu Ser Phe Pro 
    290                 295                 300                 


Met Leu Pro 
305         


<210>  154
<211>  735
<212>  DNA
<213>  artificial

<220>
<223>  nucleotide sequence encoding AVP04-50 diabody

<400>  154
agcgtgcagc tgcagcagag cgatgcggaa ctggtgaaac cgggcgcgag cgtgaaaatt       60

agctgcaaag cgagcggcta tacctttacc gatcatgcga ttcattgggt gaaacagaat      120

ccggaacagg gcctggaatg gattggctat tttagcccgg gcaacgatga ttttaaatat      180

aacgaacgtt ttaaaggcaa agcgaccctg accgcggata aaagcagcag caccgcgtat      240

ctgcagctga acagcctgac cagcgaagat agcgcggtgt atttttgcac ccgtagcctg      300

aatatggcgt attggggtca gggcacctcg gtcaccgtga gcagcggtgg cggcggcagc      360

gatatcgtga tgacccagag ctgcagcagc tgcccggtga gcgtgggcga aaaagtgacc      420

ctgagctgca aaagcagcca gagcctgctg tatagcggca atcagaaaaa ctatctggcg      480

tggtatcagc agaaaccggg tcagagcccg aaactgctga tttattgggc gagcacccgt      540

gaaagcggcg tgccggatcg ttttaccggc agcggtagcg gcaccgattt taccctgagc      600

attagcagcg tggaaaccga agatctggcg gtgtattatt gccagcagta ttatagctat      660

ccgctgacct ttggtgcggg caccaaactg gtgctgaaac gtgcggccgc actcgagcac      720

caccaccacc accac                                                       735


<210>  155
<211>  245
<212>  PRT
<213>  artificial

<220>
<223>  amino acid sequence of AVP04-50 diabody

<400>  155

Ser Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr 
            100                 105                 110         


Val Ser Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Cys 
        115                 120                 125             


Ser Ser Cys Pro Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala 
145                 150                 155                 160 


Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp 
                165                 170                 175     


Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 
            180                 185                 190         


Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr Glu Asp 
        195                 200                 205             


Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe 
    210                 215                 220                 


Gly Ala Gly Thr Lys Leu Val Leu Lys Arg Ala Ala Ala Leu Glu His 
225                 230                 235                 240 


His His His His His 
                245 


<210>  156
<211>  804
<212>  DNA
<213>  artificial

<220>
<223>  nucleotide sequence encoding AVP07-63 diabody

<400>  156
agcgtgcagc tggtgcagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc       60

tcctgtaagg gttctggata cagctttacc agctactgga tcgcctgggt gcgccagatg      120

cccgggaaag gcctggagta catggggctc atctatcctg gtgactctga caccaaatac      180

agcccgtcct tccaaggcca ggtcaccatc tcagtcgaca agtccgtcag cactgcctac      240

ttgcaatgga gcagtctgaa gccctcggac agcgccgtgt atttttgtgc gagacatgac      300

gtgggatatg cgagtagttc caacgcggca aagtggcctg aatacttcca gcattggggc      360

cagggcaccc tggtcaccgt ttcctcaggt ggaggcggtt cacagtctgt gttgacgcag      420

ccgtgcagca gctgcgcggc cccaggacag aaggtcacca tctcctgctc tggaagcagc      480

tccaacattg ggaataatta tgtatcctgg taccagcagc tcccaggaac agtccccaaa      540

ctcctcatct atggtcacac caatcggccc gcaggggtcc ctgaccgatt ctctggctcc      600

aagtctggca cctcagcctc cctggccatc agtgggttcc ggtccgagga tgaggctgat      660

tattactgtg cagcatggga tgacagcctg agtggttggg tgttcggcgg agggaccaag      720

ctgaccgtcc taggtgcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg      780

gccgcacatc accatcatca ccat                                             804


<210>  157
<211>  268
<212>  PRT
<213>  artificial

<220>
<223>  amino acid sequence of AVP07-63 diabody

<400>  157

Ser Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Tyr Met 
        35                  40                  45              


Gly Leu Ile Tyr Pro Gly Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Pro Ser Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Asp Val Gly Tyr Ala Ser Ser Ser Asn Ala Ala Lys Trp 
            100                 105                 110         


Pro Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Cys Ser Ser 
    130                 135                 140                 


Cys Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser 
145                 150                 155                 160 


Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly 
                165                 170                 175     


Thr Val Pro Lys Leu Leu Ile Tyr Gly His Thr Asn Arg Pro Ala Gly 
            180                 185                 190         


Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu 
        195                 200                 205             


Ala Ile Ser Gly Phe Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala 
    210                 215                 220                 


Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys 
225                 230                 235                 240 


Leu Thr Val Leu Gly Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu 
                245                 250                 255     


Asp Leu Asn Gly Ala Ala His His His His His His 
            260                 265             


